跳至主要内容
临床试验/NL-OMON27806
NL-OMON27806招募中不适用

Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine

MC Groningen (investigator initiated)0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Age over 18 years
  • - Clinical indication for ECT (as indicated by the treating physician/psychiatrist)
  • - A depressive episode (as assessed by the treating psychiatrist)
  • - Fluent in Dutch

排除标准

  • - Currently receiving, or having received ECT 6 months prior to the start of the treatment/study.
  • - Currently using rivastigmine, galantamine, donezepil (or another cholinesterase inhibitor).
  • - Pregnancy and/or lactation/breast feeding
  • - Suspicion of neurodegenerative disorders (as diagnosed earlier)
  • - Contraindications for ECT (recent myocardinfarct, recent cerebrovasculair accident, recent intracranial surgery, pheochromocytoma and instable angina pectoris)
  • - Contraindications for rivastigmine (bradycardia or atrioventricular (AV) conduction disorders (first degree AV-block excluded))
  • - Patients who have had an allergic reaction to rivastigmine
  • - Cognitive disorder not explained by the depressive episode

研究者

发起方
MC Groningen (investigator initiated)

相似试验